1 – 10 of 89
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer
(
- Contribution to journal › Article
- 2023
-
Mark
Restoring tumor immunogenicity with dendritic cell reprogramming
(
- Contribution to journal › Article
-
Mark
The Lund taxonomy for bladder cancer classification – from gene expression clustering to cancer cell molecular phenotypes, and back again
(
- Contribution to journal › Scientific review
-
Mark
Tumor Biomarkers for Bacillus Calmette-Guérin Response : What We Get Is Not What We Want
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re : Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020
(
- Contribution to journal › Letter
-
Mark
What is a Bladder Cancer Molecular Subtype?
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
(
- Contribution to journal › Scientific review
-
Mark
Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Restoring tumor immunogenicity with dendritic cell reprogramming
(
- Contribution to journal › Published meeting abstract
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter